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Introduction
The research on natural substances affecting cho-
lesterol metabolism for prevention of hypercholes-
terolemic atherosclerosis has particular therapeutic
importance. In particular, the identiﬁcation of die-
tary components that can be added to foods to
lower or regulate cholesterol levels has gained spe-
cial interest.
Sesame seeds in general and its major lignan ses-
amin in particular, have been associated with various
biochemical actions, mainly related to lipid metabo-
lism, including a hypocholesterolemic effect in both
human and animal-based trials (see [1, 2] for review).
Although the general hypolipidemic effect of dietary
sesamin seems to be clear in studies with rats, recent
studies pointed out discrepancies in the response to
sesamin between animal species [3] raising doubts
about a possible extrapolation of these results to hu-
mans. Additionally, the heterogeneous nature of the
sesamin preparations used in the different studies
seems to be another point to consider, since different
biological actions and mechanisms have been pro-
posed for the two epimers of dietary sesamin [4]. In
this study, we aimed to further investigate the hypo-
cholesterolemic action of sesamin minimizing the
above described variables and using only pure ses-
amin epimer and selecting low density lipoprotein
(LDL) receptor-deﬁcient mice as experimental ani-
mals. This model aims to reproduce homozygous
familial hypercholesterolemia and it is characterized
by decreased removal of cholesterol from the circu-
lation due the lack of functional LDL receptors [5]
that leads to increased serum cholesterol levels.
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j Abstract Background Sesamin,
a major lignan from sesame seeds
has been associated with choles-
terol reduction in previous re-
ports, but recent studies suggested
differences in the response to
sesamin intake depending on the
model studied as well as the nature
of the sesamin preparation used.
Aim The effect of pure sesamin
epimer on serum lipids was stud-
ied in hypercholesterolemic LDL
receptor-knockout mice under
cholesterol fed condition. Design
Animals were randomly assigned
to 4 groups, fed an atherogenic
diet containing stanol ester, ses-
amin, combination of stanol ester
and sesamin or a control diet with
no additions. Results The control
group showed an almost 3-fold
increase in serum cholesterol lev-
els due to the atherogenic diet but
no effect was seen for triglyceride
levels. Stanol ester alone or to-
gether with sesamin signiﬁcantly
attenuated the elevation of the
cholesterol levels. Conclusion
Sesamin alone did not affect the
elevation of the diet-induced cho-
lesterol level and it did not
enhance the effect of stanol ester.
j Key words cholesterol –
triglycerides – lignans –
sesamin – enterolignans –
stanol ester
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j Animal model
Female ldlr)/) mice (strain number, B6.129S7-
Ldlrtm1Her) quality SPF were obtained from the
Jackson Laboratory (Bar Harbor, Maine, US), and
maintained at the Central Animal Laboratory of Rai-
sio Benecol Ltd. (Raisio, Finland) in accordance with
European guidelines (European Treaty Series No. 123,
EU No 609/86, Ofﬁcial Journal of the European
Communities No. L 358) approved by the Animal
Care and Use Committee of the University of Turku
(Finland) approval number 1263/02. Animals were
17–18 weeks at the beginning of the study/15–20 g
and after 4 weeks of acclimatization, mice were
housed (Polycarbonate Macrolon III, Scanbur AS,
Denmark) in groups of 1–2/cage and randomly given
free access to I–IV diets for 4 weeks. Ambient tem-
perature was 21 ± 3 C, humidity ranged 55 ± 15%
and illumination consisted in 12-h dark/light cycle.
Free access to community tap water was allowed,
except during the experiments. Blood samples were
collected for the determination of the concentrations
of serum cholesterol and triglycerides at the begin-
ning and at the end of the 4-week dietary interven-
tion. Mice were sedated with CO2/O2-mixture and the
blood samples were collected from the orbital sinus
(at the beginning) or through a cardiac puncture (at
the end). At the beginning of the study the blood was
collected into 500 ll gel tubes and allowed to clot at
least for 1 h. Samples were then centrifuged for
15 min at 4000 rpm. Serum was separated and stored
at )20 C until analyses. At the end of the interven-
tion, blood samples were collected in heparin tubes
and centrifuged within 1 h. The plasma samples were
frozen at )20 C and stored until analyses. About 50 ll
was used for cholesterol and triglyceride analyses and
the rest was stored at )20 C for further analyses.
During the intervention, the animals were weighed
twice a week and observed daily (morning and
afternoon) for general well being.
j Test compounds and diets
Plant-derived stanol ester was produced by Raisio
Benecol Ltd. (Raisio, Finland). Sesamin epimer (CAS
No. 607–80-7, >95% purity, Fig. 1A) was synthesized
by Industrial Research Ltd. (Wellingtown, New Zea-
land). During acclimatization/isolation period the diet
was RM1 (E) SQC, (Special Diet Service, Witham
Essex, UK). Experimental atherogenic diets contain-
ing 0.25% of cholesterol were prepared at Raisio Be-
necol Ltd. based on Clinton-Cybulsky diet premix
(D12106pxc, Research Diets Inc., New Brunswick, NJ)
in which the test compounds were administered, as
follows: control (I) diet (n = 8), stanol ester (II) diet
(n = 8, 7 mg/kg), sesamin (III) diet (n = 8, 1 mg/kg)
and combined (IV) diet (n = 7, 7 mg/kg stanol ester
and 1 mg/kg sesamin). Diets were stored at +2 to
+8 C and allowed to warm to room temperature be-
fore delivery to the animals (twice a week) in 300-ml
glass cups attached on the cage ﬂoor.
j Rationale for dose selection
Fat and cholesterol levels in the atherogenic diet were
based on the literature [6]. The use of stanol ester as
control test model has been proven several times to
induce cholesterol reduction (Raisio Benecol Ltd.,
unpublished results) and the concentration in this
study was selected to exert sufﬁcient but not the
maximal response, enabling the possible combination
effect with sesamin. Sesamin concentration, that was
adopted from previous reports [7–9] allowing com-
parison of the results was also considered as a ratio-
nale level to be used in clinical trials.
j Analysis
Serum cholesterol and triglycerides were determined
by Ecoline CHOD-PAP and Ecoline 25 GPO-PAP as-
say kits (1.14856.0001, Merck KGaA, Darmstadt,
Germany), respectively. Control serum was Qualitrol
HS N (Merck KGaA, Darmstadt, Germany). Serum
metabolic proﬁle of lignans was carried out by HPLC
with coulometric electrode array detection [10] and
the absence of plant lignans other than sesamin epi-
mer in the diets was conﬁrmed by isotope-dilution
GC-MS [11].
j Statistics
Graph Pad Prism software version 3.02 (GraphPad
Software Inc., CA) was used for statistical data treat-
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Fig. 1 Chemical structure of sesamin epimers (A) sesamin and (B) episesamin
(or asarinin)
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  Steinkopff Verlag 2006ment. The differences in changes from the basal
concentrations during the intervention between the
groups were analyzed by ANOVA. Pair-wise com-
parisons between the groups were performed by Tu-
key’s Multiple Comparison Test. Two-way ANOVA
was used to analyze differences in the body weights
between the groups. A P-value less than 0.05 was
considered as statistically signiﬁcant. All analyses
were performed as two-sided tests.
Results
j Body weight gain
The body weights of the animals increased in all
groups during the 4-week intervention period (Fig. 2).
The increment tendency in group I was less than
those in the other groups but analysis did not reveal a
signiﬁcant group · week interaction (P = 1.00).
However, ANOVA showed a signiﬁcant group effect
(P = 0.0002), which indicates that the body weights
differed between the groups during the intervention.
j Effects of the atherogenic diet and test compounds
on serum cholesterol and serum triglyceride
concentrations
The atherogenic diet (group I) induced an almost 3-
fold increase in the s-cholesterol levels but no effect
was seen in the triglyceride levels. Stanol ester alone
(group II) or together with sesamin (group IV) sig-
niﬁcantly attenuated the elevation of the cholesterol
levels. Sesamin alone (group III) either normalize the
elevation of cholesterol levels nor did it enhance the
effect of stanol ester (group II versus group IV). Diet-
induced changes in the triglyceride levels did not
differ between groups (P = 0.89). Results are pre-
sented in Fig. 3.
j Effects of the atherogenic diet and test compounds
on plasma lignan profile after intervention
Presence of sesamin epimer in the diets resulted in the
appearance of enterolignans in plasma, although
concentrations varied greatly between animals (Ta-
ble 1). Signiﬁcantly increased levels of enterodiol
(P = 0.00), but not enterolactone were found.
Discussion
As one of the major components of sesame seeds, the
lignan sesamin has received a great deal of interest
regarding its potential as a hypocholesterolemic
agent, especially after the positive results reported by
Hirata et al. [7] in humans. Thereafter, different ap-
proaches have been used to conﬁrm this observation
in which different sources of dietary sesamin have
been used. Studies using sesame seed-based diets
provided results that are difﬁcult to discuss since the
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Fig. 2 Body weights of the animals in the different treatment groups during
the study (n = 7–8)
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Fig. 3 S-cholesterol and -triglyceride concentrations before (Basal) and after
(Intervention) the 4-week intervention with experimental diets and the
difference between basal and Intervention levels (Difference). **P < 0.001 in
comparison with Group 1 (Tukey’s Multiple Comparison Test)
J.L. Pen ˜alvo et al. 441
Sesamin and cholesterol reductionhypocholesterolemic effect could not be primarily
attributed to sesamin. As for the studies using pure
sesamin supplementation, the preparations used so
far contained a mixture of sesamin epimers (sesamin
and episesamin in a 1:1 ratio) that they are known
now to possess a different behavior both in their
metabolic fate [12] and biological action [4] sup-
porting the need to differentiate between different
sesamin epimers in future studies.
A clear hypocholesterolemic effect elicited by ses-
amin (alone or in combination with vitamin E) was
reported in studies conducted in rats [9, 13–15]o ri n
cultured rat cells [16] and similarly, other biological
effects proposed for sesamin [17–26], have also been
studied using rats as experimental animal. Very few
studies though, have used other animals than rats to
test the effects of sesamin [27, 28]. In the recent study
of Kushiro et al. [3] where sesamin was tested in
different experimental animals, results for rats were
conﬁrmed, but no effect was observed in hamsters or
mice. Only one study has investigated the hypocho-
lesterolemic effect of sesamin in humans [7] ﬁnding a
signiﬁcant effect of dietary sesamin in the reduction
of total cholesterol and LDL-cholesterol. In this study
however, dietary sesamin was administered together
with vitamin E and therefore the observed effect
might be due to the reported synergism between this
two dietary components [14] and since no separated
sesamin-group was included in the study, the hypo-
thetical action of sesamin could not be conﬁrmed.
In order to minimize the commented variables, in
the present experiment only pure sesamin epimer was
used and additionally, transgenic mice were selected
for they offer the most convenient model to investi-
gate the two proposed mechanisms for the hypocho-
lesterolemic effect of sesamin i.e. reduction of
endogenous cholesterol synthesis and reduction of
dietary absorption. Due to the lack of functional LDL-
receptors, the animals used in this trial have a spon-
taneously elevated serum cholesterol concentration,
and in addition, they are prone to diet-induced
modulation of the serum cholesterol concentration [5,
6]. Hepatic HMG-CoA reductase is the rate-limiting
enzyme in the cholesterol biosynthetic pathway and
its inhibitors are very effective in lowering plasma
cholesterol. Sesamin has been reported to inhibit
HMG-CoA reductase in rats [13] and through this
mechanism it has been proposed to reduce plasma
cholesterol. However, in this study no reduction of
serum cholesterol or triglyceride levels was observed
in the group supplemented with sesamin alone (group
III) and therefore it is concluded that sesamin does
not affect HMG-CoA reductase in this animal model.
Similarly, cholesterol supplementation (0.25%, w/w)
for 4 weeks increased plasma total cholesterol levels
approx. 3-fold in the absence of a functional LDL
receptor. However, the introduction of stanol ester in
the atherogenic diet signiﬁcantly reduced the total
plasma cholesterol level, independently of the pres-
ence of sesamin. It is known that plant stanols inhibit
the absorption of dietary cholesterol and the reab-
sorption (enterohepatic circulation) of endogenous
cholesterol from the gastrointestinal tract [29]. It
seems though that sesamin does not affect dietary
cholesterol absorption in this animal model.
The metabolism of sesamin seems to play an
essential role in its further biological action. It has
been recently suggested that in humans, sesamin is
absorbed through the portal vein reaching the liver
where extensive metabolism takes places generating
demethylenated (catechol) derivatives secreted
as glucuronidates via the bile [26]. The same metab-
olites were found after in vitro fermentation of pure
sesamin standard with human fecal inoculum and
furthermore extensive in vivo conversion to entero-
lactone was reported after sesame seed supplemen-
tation in humans [11]. We hypothesized then that the
absorption of sesamin could certainly take place via
the portal vein and that transformation to catechol
derivatives could be possible, as well as further
absorption to the general circulation where they may
exert the biological actions proposed for sesamin.
Nevertheless, in this study as in our previous trial
[11], extensive conversion of sesamin to enterolignans
was observed suggesting that non-absorbed sesamin
and possibly biliary catecholic sesamin derivatives
undergo metabolism by gut microﬂora leading to the
production and further absorption of enterolignans.
Postprandial levels of sesamin in plasma differed
considerably between rats [12] and humans [11],
suggesting a different metabolic pathway depending
on species.
Table 1 Enterolignan (enterolactone
and enterodiol) values after 4-week
intervention period nmol/l
(Mean ± SEM, n =8 )
Group n ENL
a END ENL + END
I, Control 8 4.61 ± 0.40 6.11 ± 2.10 9.18 ± 2.14
II, Stanol ester 8 3.01 ± 0.35 10.0 ± 4.69 13.0 ± 4.85
III, Sesamin 8 8.01 ± 0.98 569 ± 54.2** 577 ± 55.0**
IV, Stanol ester + sesamin 7 6.54 ± 1.99 388 ± 90.7** 394 ± 91.8**
**P < 0.001 in comparison with Group 1 (Tukey’s Multiple Comparison Test)
aENL, Enterolactone; END, enterodiol
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or a too rapid enterohepatic circulation of sesamin
could be the explanation for the lack of antihyper-
cholesterolemic effect in mice/hamsters and possibly
in humans but this hypothesis needs to be conﬁrmed.
Furthermore, the characteristics of our animal model
did not allow to study a third mechanism for cho-
lesterol reduction that sesamin could use; the incre-
ment of LDL-receptor activity. This hypothetical
mechanism has been suggested for other dietary
components [30], and it is a likely explanation of the
negative results reported in this paper.
In conclusion, possible confounding factors have
been minimized with the use of a speciﬁc animal
model and the selection a pure sesamin epimer. It can
be therefore stated that sesamin does not seem to
affect cholesterol biosynthesis or absorption in mice.
The so far contradictory results hinder the extrapo-
lation to humans, and only a clinical trial with sepa-
rate epimeric forms and the elucidation of the
complete metabolic pathway of sesamin in humans
will contribute to clarify the possible utilization of
sesamin as a hyocholesterolemic agent.
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